New HIV med stands to boost J&J, Gilead by $500M

The newly minted combination HIV drug from Gilead Sciences and Johnson & Johnson, Complera, is expected to bring in more than $500 million annually. Release | Report

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.